SR-16507 is primarily used in research settings to study its effects on dopamine receptors, specifically the D3 receptor subtype. Its application is significant in neuroscience and pharmacology, where it helps in understanding the role of D3 receptors in various neurological and psychiatric conditions. Researchers utilize SR-16507 to explore potential therapeutic avenues for disorders such as Parkinson's disease, schizophrenia, and drug addiction. By acting as a selective antagonist, it allows scientists to dissect the contributions of D3 receptors in the brain's reward and motor systems. This compound is also valuable in developing new drugs that target dopamine receptors with greater specificity and fewer side effects. Overall, SR-16507 serves as a crucial tool in advancing our knowledge of dopamine-related pathways and their implications in mental health and neurological diseases.